EBV阳性弥漫大B细胞淋巴瘤的免疫生物学:系统性抗病毒免疫缺失与LMP1驱动的抑制性髓系微环境
该研究整合外周抗病毒T细胞功能分析、高维空间蛋白质组学与体外机制建模,揭示EBV阳性DLBCL存在系统性抗病毒T细胞应答广泛受损,且肿瘤微环境中CD8⁺T细胞减少、PD-1⁺调节/耗竭T细胞扩增及PD-L1⁺/IDO1⁺巨噬细胞聚集,抑制性髓系龛优先富集于LMP1表达肿瘤细胞周围。
要点
- EBV⁺DLBCL患者抗病毒T细胞应答受损较EBV⁻患者更显著,累及潜伏和裂解期EBV抗原及非EBV病毒靶点。
- EBV⁺DLBCL微环境呈CD8⁺T细胞减少、PD-1⁺调节/耗竭T细胞扩增及PD-L1⁺/IDO1⁺巨噬细胞密集聚集。
- 抑制性髓系龛优先富集于LMP1表达肿瘤细胞周围,为EBV⁺DLBCL特有特征。
核心结论
- EBV⁺DLBCL由系统性抗病毒免疫功能障碍与LMP1依赖的抑制性肿瘤微环境汇聚驱动。
研究设计与样本
- 研究整合外周抗病毒T细胞免疫功能分析、高维空间蛋白质组学与体外机制建模。
主要发现
- EBV⁺和EBV⁻DLBCL患者均较健康对照存在广泛抗病毒T细胞应答受损,累及潜伏和裂解期EBV抗原及非EBV病毒靶点,EBV⁺患者缺陷最显著。
- EBV⁺DLBCL微环境以瘤内CD8⁺T细胞相对减少、PD-1⁺调节和耗竭T细胞群扩增及PD-L1⁺/IDO1⁺巨噬细胞密集聚集为特征。
- 与EBV⁺经典型霍奇金淋巴瘤和传染性单核细胞增多症相比,EBV⁺DLBCL巨噬细胞相关免疫抑制特征最显著且T细胞密度最低。
- 抑制性髓系龛优先富集于LMP1表达肿瘤细胞周围,其他EBV相关疾病未见此特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV⁺DLBCL) is an aggressive lymphoma with poor outcomes and an incompletely understood pathogenesis, frequently attributed to immunosenescence. However, its occurrence across all age groups suggests alternative mechanisms. Here, we integrate functional profiling of peripheral antiviral T-cell immunity with high-dimensional spatial proteomics and mechanistic in vitro modelling to define the immunological landscape of EBV⁺DLBCL. We show that both EBV⁺ and EBV⁻DLBCL patients exhibit broad impairments in antiviral T-cell responses compared with healthy controls, affecting latent and lytic EBV antigens as well as non-EBV viral targets, with deficits most pronounced in EBV⁺ patients. Spatial proteomic analysis revealed that EBV⁺DLBCL harbours a profoundly immunosuppressive tumour microenvironment characterised by relative loss of intratumoural CD8⁺ T cells, expansion of PD-1⁺ regulatory and exhausted T-cell populations and dense aggregates of PD-L1⁺/IDO1⁺ macrophages. Compared with EBV⁺ classical Hodgkin lymphoma and infectious mononucleosis, EBV⁺DLBCL displayed the most marked macrophage-associated immunosuppressive signature and the lowest T-cell density. Suppressive myeloid niches were preferentially enriched around LMP1-expressing tumour cells, a feature not observed in the other EBV-associated conditions. Together, these findings indicate that EBV⁺DLBCL is driven by the convergence of systemic antiviral immune dysfunction and an LMP1-dependent suppressive tumour microenvironment.
引用
- Fennell É, Law SC, Dowell AC, et al. Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma. Leukemia. 2026. PMID: 42271039. doi:10.1038/s41375-026-02994-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。